“…In 1993, β‐elemene was officially approved as an anti‐cancer drug in China. After that, injectable emulsions of β‐elemene were used for the first‐line treatment of pleural malignancies, chest and abdominal ascites, malignant brain tumours and cancers of the respiratory and digestive tracts, and for the second‐line treatment of cancers of female reproductive organs, breast cancer, metastatic bone cancer, skin cancer, lymphoma and leukaemia 4–6 . However, little is known regarding the tissue distribution of elemene.…”